From Well-Trodden Path to Uncharted Needs: Pharma’s Response to Rare Diseases

The pharmaceutical industry’s focus has dramatically shifted from mass-market blockbusters to addressing the needs of rare diseases. This paper compares the traditional, volume-driven approach of “Old Pharma” with the patient-centric, innovation-led strategy of “New Pharma,” highlighting the changes in economic viability and development timelines. Historically, conventional drug development, with costs over $1 billion and timelines of 10-15 years, made rare diseases commercially unappealing. However, the Orphan Drug Act of 1983 introduced incentives that fundamentally altered this landscape. When combined with advancements in targeted therapies like gene, cell, and RNA modalities, “New Pharma” for rare diseases now benefits from streamlined development. Direct costs can be as low as $47 million, and in some cases under $25 million, with notably faster launch timelines. This study presents a structured comparison across scientific, economic, and regulatory dimensions and illustrates how artificial intelligence (AI) accelerates the drug lifecycle. AI enables faster discovery, shorter clinical trial recruitment, improved patient management, and streamlined production, which is especially relevant for rare diseases, where diagnostic delays and limited patient pools remain challenges. The future of this market points to continued expansion, driven by advanced therapies and AI. This will require ongoing adaptation, ethical governance, and multi-stakeholder collaboration to ensure equitable patient benefits in these previously unexplored therapeutic areas.